AmCham Policy Forum: The Future of EU Pharma Policy – Perspectives for the Coming Years

START OF EVENT
Off

We would like to invite you to our next

Policy Forum 

with

Csaba Kontor, Health Attaché, Permanent Representation of Hungary to the EU


In November 2020, the European Commission adopted the Pharmaceutical Strategy for Europe. As the Commission claims, the strategy aims at creating a future proof regulatory framework and at supporting industry in promoting research and technologies that actually reach patients in order to fulfil their therapeutic needs while addressing market failures. It will also take into account the weaknesses exposed by the coronavirus pandemic and take appropriate actions to strengthen the system.

The Hungarian Permanent Representation will give an insight of the actions envisages in the document and touch upon connections with other initiatives such as the European Health Data Space.

Schedule:

14:00-14:05: Welcome by Zoltán Szabó, President, AmCham

14:05-14:10: Opening remarks by Etelka Dobi, Chair, Healthcare Working Group, AmCham

14:10-14:40: Presentation by Csaba Kontor, Health Attaché, Permanent Representation of Hungary to the EU

14:40-15:00: Q&A

The event will be held in English without translation.

Platform: MS Teams (the meeting link will be sent to you the day before meeting)
 

Speakers
Csaba Kontor, Health Attaché, Permanent Representation of Hungary to the EU
Csaba Kontor has been working in the field of EU pharma legislation since 2004 with regular participation in the health policy negotiations at the Council of the European Union. Before his posting to Brussels Csaba Kontor worked as the deputy head of department of the pharmaceutical department of the Ministry of Human Capacities where he was in charge of implementing EU medicines related legislative acts. Throughout his career he was involved in the negotiations of a number of regulations and directives such as those on paediatric medicines, advanced therapy medicinal products, falsified medicines, pharmacovigilance, clinical trials etc. In addition, issues related to medical devices, narcotic drugs, substances of human origin have also made part of his portfolio.
Location
Online Platform
Registration Deadline
none